Screener
Vir Biotechnology, Inc. VIR Assets Fair Value Adjustment
Assets Fair Value Adjustment at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsFairValueAdjustment.
The source filing: Vir Biotechnology, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 5:20 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053549
FAQ
- What is Vir Biotechnology, Inc.'s assets fair value adjustment?
- Vir Biotechnology, Inc. (VIR) reported assets fair value adjustment of $1.72M in Q2 2026.
- What does assets fair value adjustment mean?
- This metric captures the non-cash gains or losses resulting from changes in the fair market value of equity investments or other financial assets held by the company. It reflects market-driven volatility in the value of the company's investment portfolio. Monitoring this helps investors assess the impact of external market fluctuations on the company's financial position.
Ask your AI about Vir Biotechnology, Inc.'s assets fair value adjustment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude